Gradian Diagnostics (“Gradian”) was born from the idea that many emerging medical technology companies would benefit, not only from financial, but also managerial, sales and marketing skills to fully reveal their potential.  Molzym is Gradian´s first acquisition.

Gabriel Tirouflet (CEO of Gradian and Molzym) “After 6 months of intensive work with the operating team, I´m convinced Molzym will play a great role in current Healthcare system changes, bringing a complement to culture with molecular diagnostic capacity, towards precision medicine.”

Jakob Glatz (Chairman of the Board) “We’re very proud of Molzym team’s mindset, which contributes to a new era of our global Healthcare systems, especially in those challenging times. The change of Board clearly emphasizes the reinforcing of the company strategy, fully dedicated to long-term growth and sustainability. Company has already restructured and set-up innovative solutions with one common goal: bring Molzym solutions for microbial molecular diagnostics at the disposal of any laboratories worldwide, for improved patient care. The Board is glad to bring its expertise in finance and management to lead Molzym life-changing technology to its next level of success.”